Further studies in animal models are warranted to examine whether antagonizing hepatic MAP4K4 signaling may be beneficial in NAFLD as well as other metabolic diseases, where liver lipotoxicity is being the principal pathological mechanism. This evidence concerns the gene MAP4K4 and metabolic dysfunction-associated steatotic liver disease.